Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer

Archives of Otolaryngology - Head and Neck Surgery

Volumn 135, Issue 12, 2009, Pages 1209-1217

  Givens, Daniel J ^a   Karnell, Lucy Hynds ^a   Gupta, Anjali K ^a   Clamon, Gerald H ^a   Pagedar, Nitin A ^a   Chang, Kristi E ^a   Van Daele, Douglas J ^a   Funk, Gerry F ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CREATININE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CREATININE BLOOD LEVEL; DEHYDRATION; DENTITION; DEPRESSION; DESQUAMATION; DIET; DRUG FATALITY; DRUG FEVER; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLUID RESUSCITATION; FOLLOW UP; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HEAD AND NECK CANCER; HEALTH STATUS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OROPHARYNX CANCER; OTOTOXICITY; OUTCOME ASSESSMENT; PNEUMONIA; QUALITY OF LIFE; RADIATION INDUCED EMESIS; SIDE EFFECT; SURVIVAL RATE; TERTIARY HEALTH CARE; THERAPY DELAY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TOOTH PROSTHESIS; TRACHEOSTOMY; TREATMENT OUTCOME; TRISMUS;

AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RADIOTHERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 73949092081     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archoto.2009.174     Document Type: Article

References (44)

1. Trotti A, Pajak TF, Gwede CK, et al. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol. 2007;8(7):613-624.
2. Kubicek GJ, Machtay M. New advances in high-technology radiotherapy for head and neck cancer. Hematol Oncol Clin North Am. 2008;22(6):1165-1180.
3. Eisbruch A, Schwartz M, Rasch C, et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys. 2004;60(5): 1425-1439.
4. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys. 2007;68(5):1289-1298.
5. Anand AK, Chaudhoory AR, Shukla A, et al. Favourable impact of intensitymodulated radiation therapy on chronic dysphagia in patients with head and neck cancer. Br J Radiol. 2008;81(971):865-871.
6. Chao KS, Low DA, Perez CA, Purdy JA. Intensity-modulated radiation therapy in head and neck cancers: the Mallinckrodt experience. Int J Cancer. 2000;90 (2):92-103.
7. Dawson LA, Anzai Y, Marsh L, et al. Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2000;46(5): 1117-1126.
8. Huang K, Lee N, Xia P. Intensity-modulated radiotherapy in the treatment of oropharyngeal carcinoma: a single institutional experience. Int J Radiat Oncol Biol Phys. 2003;57(suppl):S302.
9. Garden AS, Harris J, Vokes EE, et al. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol. 2004;22(14):2856-2864.
10. Zhen W, Lydiatt W, Lydiatt D. A preliminary analysis of patterns of failure in patients treated with intensity modulated radiotherapy (IMRT) for head and neck cancer: the University of Nebraska Medical Center experience. Int J Radiat Oncol Biol Phys. 2004;60(suppl):S318-S319.
11. Yao M, Dornfeld KJ, Buatti JM, et al. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma: the University of Iowa experience. Int J Radiat Oncol Biol Phys. 2005;63(2):410-421.
12. de Arruda FF, Puri DR, Zhung J, et al. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys. 2006;64(2):363-373.
13. Garden AS, Morrison W, Wong PF, et al. Disease-control rates following intensitymodulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007;67(2):438-444.
14. Hodge CW, Bentzen SM, Wong G, et al. Are we influencing outcome in oropharynx cancer with intensity-modulated radiotherapy? an inter-era comparison. Int J Radiat Oncol Biol Phys. 2007;69(4):1032-1041.
15. Rusthoven KE, Raben D, Ballonoff A, Kane M, Song JI, Chen C. Effect of radiation techniques in treatment of oropharynx cancer. Laryngoscope. 2008;118 (4):635-639.
16. Schoenfeld GO, Amdur RT, Morris CG, Li JG, Hinerman RW, Mendenhall WM. Patterns of failure and toxicity after intensity modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;71(2):377-385.
17. Lee N, Chuang C, Quivey JM, et al. Skin toxicity due to intensity-modulated radiotherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys. 2002; 53(3):630-637.
18. Pignon JP, Bourhis J, Domenge C, Designé L; MACH-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamouscell carcinoma: three meta-analyses of updated individual data. Lancet. 2000; 355:949-955.
19. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L; Cancer Care Ontario Practice Guideline Initiative Head and Neck Cancer Disease Site Group. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck. 2001;23(7):579-589.
20. Pignon JP, le Maitre A, Bourhis J; MACH-NC Collaborative Group. Metaanalyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys. 2007;69(2)(suppl):S112-S114.
21. Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck [published online January 21, 2006]. BMC Cancer. 2006; 6:28. doi:10.1186/1471-2407-6-28.
22. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349(22):2091-2098.
23. Funk GF, Karnell LH, Christensen AJ, Moran PJ, Ricks J. Comprehensive head and neck oncology health status assessment. Head Neck. 2003;25(7):561-575.
24. Funk GF, Karnell LH, Smith RB, Christensen AJ. Clinical significance of health status assessment measures in head and neck cancer: what do quality-of-life scores mean? Arch Otolaryngol Head Neck Surg. 2004;130(7):825-829.
25. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36), I: conceptual framework and item selection. Med Care. 1992;30(6):473-483.
26. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: Nimrod Press; 1993.
27. Ware JE, Kosinski M, Dewey JE. How to Score Version Two of the SF-36 Health Survey. Lincoln, RI: Quality Metric Inc; 2000:75.
28. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
29. Kendall PC, Hollon SD, Beck AT, Mammen CL, Ingram RE. Issues and recommendations regarding use of the Beck Depression Inventory. Cognit Ther Res. 1987;11:289-299.
30. Gibbs IC, Le Q, Terris DJ, et al. The influence of overall radiation time (ORT) in patients treated with chemoradiotherapy for squamous cancer of the head and neck. Int J Radiat Oncol Biol Phys. 1999;45(suppl 3):376-377.
31. Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys. 2007;68 (3):654-661.
32. Russo G, Haddad R, Posner M, Machtay M. Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist. 2008;13(8):886-898.
33. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol (Madr). 1988;27(2):131-146.
34. Tarnawski R, Fowler J, Skladowski K, et al. How fast is repopulation of tumor cells during the treatment gap? Int J Radiat Oncol Biol Phys. 2002;54(1):229-236.
35. Bernier J. Current state-of-the-art for concurrent chemoradiation. Semin Radiat Oncol. 2009;19(1):3-10.
36. Nonzee NJ, Dandade NA, Patel U, et al. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center [published correction appears in Cancer. 2009;115(2):280]. Cancer. 2008;113(6): 1446-1452.
37. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity, and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003; 66(3):253-262.
38. Vera-Llonch M, Oster G, Hagiwara M, Sonis S. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer. 2006;106(2): 329-336.
39. Lee NY, O'Meara W, Chan K, et al. Concurrent chemotherapy and intensitymodulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys. 2007;69(2):459-468.
40. Huang K, Xia P, Chuang C. Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California-San Diego experience. Cancer. 2008;113(3):497-507.
41. Zuur CL, Simis YJ, Verkaik RS, et al. Hearing loss due to concurrent daily lowdose cisplatin chemoradiation for locally advanced head and neck cancer. Radiother Oncol. 2008;89(1):38-43.
42. McWhinney SR, GoldbergRM,McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009;8(1):10-16.
43. Eisbruch A, Lyden T, Bradford CR, et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2002;53(1):23-28.
44. Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? a comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004; 22(17):3485-3490.